Trial for bleeding disorder drug in toddlers pulled before it started
NCT ID NCT02472665
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to test how FANHDI, a clotting factor concentrate, works in children under 6 with severe von Willebrand disease (types 2 or 3). The goal was to measure how the drug moves through the body and how well it controls bleeding. However, the trial was withdrawn before enrolling any participants, so no data were collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- FANHDI (a plasma-derived factor VIII/von Willebrand factor concentrate)
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VON WILLEBRAND DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital Sant Joan de Déu Barcelona
Esplugues de Llobregat, Barcelona, 08950, Spain
-
Hospital Universitario La Paz
Madrid, Spain
-
Hospital Universitario Miguel Servet
Zaragoza, Spain
-
Hospital Universitario Virgen del Rocío
Seville, Sevilla, 41013, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Newborn screening study aims to catch rare diseases at birth
- Tiny camera may spot hidden bleeding in rare blood disorder
- New hope for kids with rare bleeding disease: study tests rVWF therapy
- Could a simple shot replace IV treatments for severe bleeding disorder?
- New study tracks joint replacement success in bleeding disorder patients
- New hope for toddlers with rare bleeding disorder: wilate shows promise